Clinical characteristics of patients treated with natalizumab (groups T0, T6).

<p>Clinical characteristics of patients treated with natalizumab (groups T0, T6).</p

MSRV-type mRNA expression by PBMC from IM patients and healthy donors (HD).

<p>The amounts of MSRV-type HERV-Wenv transcripts were evaluated by discriminatory real time RT-PCR, and normalized by the 2^−ΔCt method (see Methods for details). Data are expressed as medians (line), with maximum and minimum values (whiskers); boxes represent interquartile range of the samples. Statistical significance was evaluated by the Mann-Whitney U-test for comparison of two groups, and by the Kruskal-Wallis test for three or four groups. (<b>A</b>) Comparison of IM patients (N = 17) and all healthy donors (HD, N = 24). (<b>B</b>) Comparison of IM patients (N = 17) and HD donors stratified according to plasmatic anti-EBNA-1 IgG titers, as EBV-negative (EBV−, N = 9), <600 IU/ml (N = 7), and >600 IU/ml (N = 8). Kruskall-Wallis test gave p = 0.0005 for all four groups, and p = 0.014 for the three HD groups.</p

Demographic and clinical characteristics of patients hospitalized with infectious mononucleosis and of healthy controls.

a<p>data are expressed as EBNA-1 DNA copies/ml of plasma. Detection limits: 100 copies/ml of plasma;</p>b<p>bl, borderline;</p>c<p>not done.</p

Population kinetic parameters for the best HCV and ALT kinetic model.

<p>Population kinetic parameters for the best HCV and ALT kinetic model.</p

Decrease of viral load and ALT at different time points under treatment according to NS5A-inhibitors and interferon administration.

<p>These graphs shows the median of predictions of ALT and HCV-RNA in different groups of treatment obtained by simulations from the parameter estimates of the two models. ALT, alanine transaminase; IFN, interferon.</p

Biphasic kinetics of HCV-RNA decay, and ALT drop during all-DAA and TVR+PR treatment and follow-up.

<p>In <i>upper panels</i>, median values with 95% confidence interval of HCV-RNA (black dots) and ALT (grey squares) during all-DAAs (panel <b>A</b>) and TVR+PR (panel <b>B</b>) treatment are reported. End of follow-up is at 12 weeks after treatment discontinuation. Black dotted line represents the lower limit of detection of HCV-RNA (12–15 IU/ml). Grey dotted line represents normality range of ALT values in females (45 IU/ml). Histograms in <i>lower panels</i> represent the percentages of patients with HCV-RNA below the lower limit of detection (panel <b>C</b>) and with normal ALT values (panel <b>D</b>) during all-DAAs (black) and TVR+PR (grey) treatment. Normal ALT values were considered as <55 IU/ml in men, and <45 IU/ml in women. ALT, alanine transaminase; DAA, direct-acting antivirals; EOT, end of treatment; IU, international units; LLOD, lower limit of detection (<12–15 IU/ml, not detected); PR, pegylated interferon and ribavirin; TVR, telaprevir. * p-value <0.05 by Fisher exact test; ** p-value ≤0.001 by Fisher exact test.</p

Cox analysis for factors influencing ALT normalization during treatment.

<p>Cox analysis for factors influencing ALT normalization during treatment.</p

Predicted kinetic profiles obtained by simulations from the viral and ALT kinetic models.

<p>(panel <b>A</b>) Different viral kinetics according to HCV-genotypes, NS5A-inhibitors and interferon administration, (panel <b>B</b>) Different ALT kinetics according to NS5A-inhibitors and interferon administration. ALT, alanine transaminase; IFN, interferon.</p